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LPD from Taiwan health care payer’s perspective. Methods: A Markov was designed 
to simulate outcomes of two options in a hypothetical cohort of adult CKD patients 
with eGFR 15-29 mL/min/1.73m2: (1) Initiation of LPD plus KA, and (2) watchful-waiting 
on LPD and initiation of KA at eGFR < 15 mL/min/1.73m2. The Markov states included 
CKD stage 4 and 5, hemodialysis, and death. Total direct medical cost and quality-
adjusted life-years (QALYs) gained were calculated over a maximum period of 10 
years. Model inputs were derived from literature. Sensitivity analyses evaluated the 
impact of uncertainty in all model variables. Results: In base-case analysis, early KA 
initiation group (3.926 QALYs and USD548,191) gained higher QALYs and cost less than 
the watchful-waiting group (3.787 QALYs and USD887,608) (USD1= NTD30). Sensitivity 
analysis indicated that early KA initiation at eGFR at 17-29 mL/min/1.73m2 would 
be the preferred cost-effective option if reduction of eGFR decline associated with 
LPD plus KA was 4% or above. When KA was initiated at eGFR 15-17 mL/min/1.73m2, 
it would remain cost-effective if the reduction of eGFR decline associated with LPD 
plus KA was 13.5% or above. 10,000 Monte Carlo simulations showed early KA initia-
tion group to be less costly with higher QALY gained than watchful-waiting group by 
USD333,655 (95% CI 332,174-335,137) and 0.160 (95% CI 0.140-0.180) QALYs, respec-
tively. ConClusions: KA Initiation with LPD in CKD patients as early as eGFR 15-29 
mL/min/1.73m2 seems to be cost-effective in Taiwan.
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objeCtives: Hyperphoshatemia or elevated phosphorus in the blood is prevalent 
in patients with chronic kidney disease - mineral and bone disorder (CKD-MBD) 
and independently and significantly contributes to morbidity and mortality. The 
objective of this study is to perform cost - minimization analysis of the newly 
available medicines sevelamer carbonate (SC) and lanthanum carbonate (LC), for 
the treatment of hyperphosphatemia in CKD patients not on dialysis (CKD-ND) in 
Bulgaria. Methods: The results of the head-to-head clinical trial conducted by 
Spraque (2009) demonstrated equivalent efficacy and safety profiles between the 
two treatment options. To differentiate the cost in high dose and low dose thera-
peutic regimes was performed a cost-minimization analysis. Based on that was 
forecasted the expected cost savings for four years period. Discounting rate of 3.5% 
was applied. The robustness of the Results was tested through sensitivity analysis 
(SA) using Tornado diagram. Results: The estimated treatment cost per patient/
per year with SC and LC was 1441,75€ and 1569,50€ respectively at the low dose 
regimen (4000 mg of SC vs. 2000 mg of LC), while within the high dose regimen (6400 
mg of SC vs. 3000mg of LC) it was 2306,80€ and 2354,25€ respectively. Expected cost 
savings (discounted) for the four years period within the assumed market shares 
was between 1 348 794€ and 2 696 431€ at the low dose regimen, while at the high 
dose regimen the estimated cost savings was between 501 593€ and 1 001 532€ 
respectively. The results of SA (discounted) show that the major cost drivers in the 
treatment of hyperphosphatemia were the unit costs of SC and LC. ConClusions: 
The equal efficacy and lower cost of sevelamer carbonate than lanthanum carbon-
ate when used for treatment of hyperphosphatemia in patients with CKD -ND in 
Bulgaria should made the sevelamer carbonate a preference alternative.
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objeCtives: In a 36-month, open label RCT that involved 213 patients in stage 3-4 
nondialysis-dependent CKD (NDD-CKD) (INDEPENDENT study), sevelamer showed 
lower rates of all-cause mortality and dialysis inception vs. calcium carbonate. The 
aim of this study was to assess the cost-effectiveness of sevelamer vs. calcium car-
bonate in NDD-CKD patients with hyperphosphatemia in Spain. Methods: A 
Spanish National Health System perspective and lifetime horizon was chosen for 
the analysis. A Markov model was developed considering health states of “alive with 
NDD-CKD”, “alive with dialysis-dependent CKD”, and “dead”). All-cause mortal-
ity, dialysis inception, hospitalization (frequency and length of stay [LOS]), and drug 
dosage data were taken from the INDEPENDENT study. All-cause mortality and dialysis 
inception were extrapolated beyond 36 months using Weibull regression analysis. Local 
costs (euros, 2014) were applied to pharmaceutical, hospitalization and dialysis utiliza-
tion. Health utility data was taken from the published literature. Costs and effects were 
discounted at a rate of 3%. Results: In the base case analysis sevelamer was associ-
ated with increased survival, delay in dialysis inception, fewer hospitalizations, shorter 
LOS, 2,12 life years gained (LYG) and 1,61 quality-adjusted life years gained (QALYG) vs. 
calcium carbonate. Increased survival translated into more treatment time and dialysis 
sessions vs. calcium carbonate, resulting in an incremental cost of 33.687 € . The incre-
mental cost per LYG for sevelamer vs. calcium carbonate was 15.897 € and the incremen-
tal costs per QALY gained was 20.883 € . Sensitivity analysis showed that sevelamer was 
more effective and less costly (i.e., dominant) vs. calcium carbonate in time horizons 
< 6 years. ConClusions: The Spanish analysis showed that sevelamer is a cost-effec-
tive strategy vs. calcium carbonate for the treatment of hyperphosphatemia in patients 
with NDD-CKD, with cost-effectiveness ratios well below the accepted thresholds of 
30.000-45.000 € /QALY gained.
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performed using Monte Carlo technique. Results: Annual patient costs of MMF 
were: $7,746.75, $7,993.03, $7,694.19 and $7,939.14 USD. For MPS were: $7,673.35, 
$7,989.92, $7,605.80 and $7,920.64 USD with an incremental efficacy of 0.07 less graft 
rejection in APD, IPMED, IPMAD and hemodialysis respectively in one year horizon. 
PSA shows consistency on model results. ConClusions: MPS was a dominant 
alternative having lower costs and more effectiveness than MMF. These results 
show possibilities to achieve cost-savings and a potential clinical benefit in renal 
transplants, from the perspective of the Mexican public health system, in specific 
from IMSS. *IMSS (Mexican Institute of Social Security)
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objeCtives: Uncontrolled NDO may lead to medical sequelae, such as upper 
urinary tract complications and renal failure. Treatment choices include BSC 
(comprised of behavioural therapy and pads, alone or in combination with clean 
intermittent catheterisation, and possibly with anticholinergics), onabotulinum-
toxinA, and surgery. The study’s objective was to determine the cost-effectiveness 
of onabotulinumtoxinA 200 U vs. BSC among patients inadequately managed with 
anticholinergics in a UK setting. Methods: A Markov model was developed to 
compare onabotulinumtoxinA + BSC to BSC alone, with surgery as a downstream 
option. Efficacy and safety inputs were based on Phase 3 trials. Utility values were 
derived from a UK preference elicitation study. Costs were obtained from various 
NHS sources. Model uncertainty was examined through deterministic and proba-
bilistic sensitivity analyses. Results: The base case incremental cost-effective-
ness ratio (ICER) was £3,856, with an incremental cost of £1,692 and incremental 
benefits of 0.4387 quality-adjusted life-years (QALYs) for onabotulinumtoxinA 
+ BSC compared with BSC alone over 5 years. A lifetime horizon yielded an 
ICER of £2,739 per QALY. Univariate sensitivity analyses indicated that the main 
cost drivers are mean monthly use of catheters and treatment administration 
costs. Probabilistic sensitivity analysis suggested there would be 100% probability 
of the ICER being ≤ £10,000. ConClusions: Our analysis suggests that onabotu-
linumtoxinA + BSC is a cost-effective treatment option, compared with BSC alone 
for patients with NDO who are inadequately managed with anticholinergics in 
the UK.
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objeCtives: To assess the cost-effectiveness of botulinum toxin type A (BTXA; 
BOTOX®) 100 U in the treatment of idiopathic overactive bladder (OAB) with urinary 
incontinence (UI) among patients inadequately managed by anticholinergic therapy 
in France. Methods: A 10 year Markov model divided into 3-month cycles was 
developed to predict the long-term costs and health outcomes of BTXA + best sup-
portive care (BSC; comprising behavioural therapy, incontinence pads, continued 
anticholinergic therapy for some patients and, occasionally, catheters) versus BSC 
alone from a societal perspective (excluding productivity loss) in France. Health 
states were determined by daily number of UI episodes. Patients discontinuing BTXA 
and a proportion of patients receiving BSC alone were eligible to receive downstream 
sacral nerve stimulation (SNS). Costs and health outcomes were discounted at 4% 
annually. The modelled cohort comprised patients from two phase 3 clinical trials of 
BTXA and a long-term extension study. Literature, published guidelines and expert 
advice informed all other model assumptions. Incontinence Quality of Life (I-QOL) 
data from the trials were mapped to 5-dimension EuroQol questionnaire (EQ-5D) 
utility values using a published algorithm. Sensitivity analyses assessed the impact 
of varying model parameters as well as providing a direct comparison between BTXA 
+ BSC and SNS. Results: BTXA + BSC was economically dominant compared with 
BSC alone in the base case (quality-adjusted life-year [QALY] gain: +0.198; cost differ-
ence: –€ 1937). BTXA + BSC was also economically dominant when compared directly 
with SNS (QALY gain: +0.143; cost difference: –€ 8973). Probabilistic sensitivity analy-
sis indicated that the incremental cost-effectiveness ratio has approximately a 90% 
likelihood of being below € 20 000 per QALY gained. ConClusions: In France, BTXA 
+ BSC is economically dominant over BSC alone for patients with OAB, symptoms 
of UI and an inadequate response to anticholinergic therapy.
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objeCtives: In Taiwan, chronic kidney disease (CKD) patients with estimated glo-
merular filtration rate (eGFR) < 15 mL/min/1.73m2 are suggested to be managed with 
low-protein diet (LPD) (≤ 0.6 g/kg/day) plus ketoanalogs (KA) supplement. Recent clini-
cal findings showed early KA initiation with LPD at eGFR 15-29 mL/min/1.73m2 would 
significantly slow down eGFR decline. We compared cost-effectiveness of KA initiation 
at eGFR 15-29 mL/min/1.73m2 versus eGFR < 15 mL/min/1.73m2 in CKD patients on 
